Oliver Sartor, MD

Evolution of Personalized Treatment in Advanced PC

Current Approaches for Patients With mCRPC 

Differentiating Somatic and Germline Testing in PC

Genomic Testing in mPC: When and How Often?

What is a Phenotypic Biomarker? 

PSMA-Imaging as a Noninvasive Detection of Metastasis

Videos

Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.

Targeting PSMA in Advanced Prostate Cancer

A. Oliver Sartor, MD, Medical Director of Tulane Cancer Center, explains why primary care physicians and oncologists/urologists have differences of opinion when it comes to prostate-specific antigen (PSA) testing.

Internists will point out that PSA testing has many false positives and explaining the pros and cons of the test to patients is too time consuming, says Sartor. However, oncologists think about PSA everyday, he says.

Randomized trial data from Sweden showed a clear benefit to PSA testing in younger men, says Sartor. The PLCO trial, which many use to argue against PSA, was extremely contaminated as many patients in the control arm received PSA, and therefore should not be considered, explained Sartor.

PSA has the ability to save lives, says Sartor, but active surveillance must be used wisely for patients with low-risk disease.

A. Oliver Sartor, MD, Medical Director of Tulane Cancer Center, explains why primary care physicians and oncologists/urologists have differences of opinion when it comes to prostate-specific antigen (PSA) testing.


Dr. Oliver Sartor on Considerations, Controversy With PSA Testing in Prostate Cancer 

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses how radium-223 dichloride became deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC). The treatment was tested in an open-label phase I/II trial where patients were given 6 additional doses of radium-223 on top of their original 6-dose regimen.

Dr. Oliver Sartor on Doubling the Dosage of Radium-223 in Patients With CRPC

Oliver Sartor, MD, medical director, Tulane University, discusses a recent study in predicting effective treatments through a non-selected circulating tumor cell test. The study was presented as Abstract 163 at the 2016 ASCO GU conference in San Fransisco by first author Howard I. Scher. The abstract aims to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies for patients with metastatic castration resistant prostate cancer.

Sartor says the test would lay out molecular data regarding a patient's malignancy and allow community oncologists to determine what would be the best course of treatment. He added that the hope for this study is to replace the "trial and error" method of treatment with something more concrete.

Oliver Sartor, MD | Authors

Articles

Targeting PSMA in Advanced Prostate Cancer

Dr. Oliver Sartor on Considerations, Controversy With PSA Testing in Prostate Cancer

Dr. Oliver Sartor on Doubling the Dosage of Radium-223 in Patients With CRPC

Dr. Oliver Sartor on the Future of Identifying Phenotypic and Genomic Heterogeneity in mCRPC